- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04832659
Assessment of Biomarkers in Children to Help Parents Quit Tobacco (ABC Quit)
February 7, 2023 updated by: Jonathan P. Winickoff, MD, MPH, Massachusetts General Hospital
This randomized controlled trial will test whether adding biomarker measurement and informed outreach for tobacco smoke exposure as part of routine practice increases identification and improves treatment, effectiveness, and sustainability of a parental tobacco control intervention that will be integrated into pediatric practice.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
This trial will examine the effectiveness of systematic cotinine testing of children 12 years old or younger using blood already collected at any visit to a practice that sees pediatric patients where there is a clinically indicated blood draw.
We hypothesize that providing cotinine biomarker results to pediatricians, personalized cotinine feedback to parents about their child's toxin exposure, and offering support to all household tobacco users to quit tobacco use (Biomarker Informed Outreach (BIO)) when added to the Clinical Effort Against Secondhand Smoke Exposure (CEASE) intervention will increase delivery of tobacco cessation assistance, increase household cessation, reduce tobacco smoke exposure in children, and be cost-effective.
This is a 2-arm randomized controlled trial with family-level randomization to either CEASE+BIO or CEASE arms at the time of the child's baseline visit.
To compare the effectiveness of CEASE+BIO vs. CEASE, we will follow-up with enrolled parents 12 months later to assess parental quit rate and children's tobacco smoke exposure.
Study Type
Interventional
Enrollment (Anticipated)
868
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Emara Nabi, PhD
- Phone Number: 617-726-3419
- Email: enabi@mgh.harvard.edu
Study Locations
-
-
Ohio
-
Cleveland, Ohio, United States, 44109
- Recruiting
- MetroHealth System
-
Contact:
- Emara Nabi, PhD
- Phone Number: 617-726-3419
- Email: enabi@mgh.harvard.edu
-
Principal Investigator:
- Jonathan P Winickoff, MD, MPH
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Child 12 years old or younger presenting for a visit.
- Child scheduled for or has had a clinically indicated blood draw at that visit
- Parent/legal guardian of the child.
- Parent/legal guardian is a current smoker (past 7 days).
Exclusion Criteria:
- Parent/legal guardian is non-English speaking.
- Parent/legal guardian is less than 18 years of age.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: CEASE
Those assigned to the Active Comparator arm will receive the CEASE intervention.
|
The CEASE intervention is considered the accepted standard of care according to national treatment guidelines.
Parents of a child scheduled to be seen at a participating pediatric practice will be provided with a brief intake survey.
Office staff and clinicians will be trained how to utilize the intake survey system and how to provide evidence-based cessation assistance to parents who smoke.
The brief intake survey will conduct screening to identify household smoking.
The CEASE system will provide (1) Automatic documentation of smoking cessation services requested; (2) Automatically generated prescription for nicotine replacement therapy for parents who smoke (unless they opt out of receiving the prescription); (3) Automated enrollment in the state's free tobacco Quitline and the SmokeFreeTXT program, a text message program offered by the National Cancer Institute.
|
EXPERIMENTAL: CEASE + BIO
Those assigned to the Experimental CEASE + BIO arm will receive the CEASE intervention plus Biomarker Informed Outreach (BIO).
|
The CEASE intervention is considered the accepted standard of care according to national treatment guidelines.
Parents of a child scheduled to be seen at a participating pediatric practice will be provided with a brief intake survey.
Office staff and clinicians will be trained how to utilize the intake survey system and how to provide evidence-based cessation assistance to parents who smoke.
The brief intake survey will conduct screening to identify household smoking.
The CEASE system will provide (1) Automatic documentation of smoking cessation services requested; (2) Automatically generated prescription for nicotine replacement therapy for parents who smoke (unless they opt out of receiving the prescription); (3) Automated enrollment in the state's free tobacco Quitline and the SmokeFreeTXT program, a text message program offered by the National Cancer Institute.
Children randomized to the CEASE + BIO group will have leftover blood from an already collected blood sample that was taken for a clinically indicated blood draw analyzed for cotinine.
Parents of children in the CEASE +BIO group will receive a report of biomarker results followed by proactive outreach from a BIO counselor.
The BIO counselor will explain the laboratory results and refer all parents in the household who smoke to tobacco treatment through the parent's primary care provider and/or the state quitline.
The BIO counselor will troubleshoot any barriers to obtaining nicotine replacement therapy that may have been prescribed as part of the CEASE protocol and will promote strict smoke-free and vape-free home and car policies.
BIO counselors will conduct a maximum of 6 calls per enrolled smoker.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Parental quit rate
Time Frame: 12 months
|
Parental 7-day point-prevalence tobacco abstinence at 12-month follow-up, biochemically confirmed
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Screening for tobacco use
Time Frame: 12 months
|
Rates of parents receiving screening for tobacco use, assessed by validated surveys of parents
|
12 months
|
Counseling about cessation
Time Frame: 12 months
|
Rates of receiving counseling about smoking cessation, assessed by validated surveys of parents
|
12 months
|
Counseling about smoke-free/vape-free homes and cars
Time Frame: 12 months
|
Rates of receiving counseling about smoke-free and vape-free homes and cars, assessed by validated surveys of parents
|
12 months
|
Nicotine replacement therapy prescriptions
Time Frame: 12 months
|
Rates of delivery of nicotine replacement therapy prescriptions, assessed by validated surveys of parents
|
12 months
|
State quitline referrals
Time Frame: 12 months
|
Rates of referrals to the state quitline, assessed by validated surveys of parents
|
12 months
|
Children's tobacco smoke exposure
Time Frame: 12 months
|
Child's tobacco smoke exposure, assessed by child's blood cotinine level
|
12 months
|
Smoke-free and vape-free homes and cars
Time Frame: 12 months
|
Smoking and vaping inside homes and cars, strictly enforced rules prohibiting smoking and vaping in homes and cars, assessed by validated surveys of parents
|
12 months
|
Identification of other household smokers
Time Frame: 12 months
|
Rate of identifying other household members who smoke, assessed by self-report of the enrolled parents
|
12 months
|
Smoking cessation among other household members
Time Frame: 12 months
|
Quit rate among other household members who had smoked, assessed by self-report of the enrolled parents
|
12 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cost per quit
Time Frame: 45 months
|
The cost per quit of CEASE+BIO relative to CEASE will compare favorably to other health system tobacco cessation interventions (< $5,000 per quit)
|
45 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
January 20, 2023
Primary Completion (ANTICIPATED)
February 1, 2026
Study Completion (ANTICIPATED)
February 1, 2026
Study Registration Dates
First Submitted
March 25, 2021
First Submitted That Met QC Criteria
April 1, 2021
First Posted (ACTUAL)
April 6, 2021
Study Record Updates
Last Update Posted (ACTUAL)
February 8, 2023
Last Update Submitted That Met QC Criteria
February 7, 2023
Last Verified
February 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2021P000004/MGH
- R01CA248742 (NIH)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
The study dataset will be made publicly available with the approval the Institutional Review Board of record at Massachusetts General Hospital and Health Information Services Group (responsible for ensuring HIPPA compliance).
The data will be de-identified and validated.
The dataset will include a codebook that defines the variables and describes the structure of the dataset.
IPD Sharing Time Frame
Data will become available at the conclusion of the study, after the research findings have been published.
IPD Sharing Access Criteria
The dataset will be made publicly available.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Tobacco Dependence
-
Washington University School of MedicineNational Cancer Institute (NCI); National Institutes of Health (NIH)CompletedSmoking | Smoking Cessation | Tobacco Use | Tobacco Smoking | Tobacco Use Cessation | Nicotine Dependence | Tobacco Dependence | Smoking, Tobacco | Nicotine Use Disorder | Nicotine Dependence, Cigarettes | Smoking, Cigarette | Nicotine Dependence Tobacco Product | Tobacco; Use, Rehabilitation | Smoking (Tobacco) Addiction and other conditionsUnited States
-
Juul Labs, Inc.CelerionCompletedTobacco Use | Smoking, Tobacco | Nicotine Dependence, Other Tobacco ProductUnited States
-
Juul Labs, Inc.Rose Research Center, LLCCompletedTobacco Use | Tobacco Smoking | Nicotine Dependence, Other Tobacco ProductUnited States
-
University of Nevada, RenoNot yet recruitingTobacco Dependence Caused by CigarettesUnited States
-
Centro Hospitalar Lisboa OcidentalCompleted
-
Medical University InnsbruckCompletedSubstance Abuse | Nicotine Dependence | Tobacco Dependence | Substance DependenceAustria
-
Juul Labs, Inc.CompletedTobacco Use | Tobacco Smoking | Nicotine Dependence | Nicotine Dependence, CigarettesNew Zealand
-
Juul Labs, Inc.CompletedTobacco Use | Tobacco Smoking | Nicotine Dependence | Nicotine Dependence, CigarettesNew Zealand
-
Assistance Publique - Hôpitaux de ParisRecruitingAdults (Male and Female Subjects) With Tobacco DependenceFrance
-
University of Wisconsin, MadisonCompleted
Clinical Trials on CEASE
-
St. Justine's HospitalActive, not recruitingTobacco Cessation | Tobacco Use | Smoking, Tobacco | Second Hand Tobacco Smoke | VapingCanada
-
Massachusetts General HospitalNational Cancer Institute (NCI); National Institutes of Health (NIH); American...CompletedTobacco DependenceUnited States
-
University of VermontNational Institute on Drug Abuse (NIDA); National Institutes of Health (NIH)Completed
-
Dana-Farber Cancer InstituteMassachusetts General Hospital; Brigham and Women's HospitalActive, not recruitingSmoking Cessation | Lung CancerUnited States
-
Massachusetts General HospitalFlight Attendant Medical Research InstituteCompleted
-
Lung Biotechnology PBCCompletedPulmonary Arterial HypertensionUnited States, Belgium, Ireland